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Abstract
VEGF-induced angiogenesis significantly contributes to tumor growth, invasion and metastasis.
However, little is known about its hematopoietic activity during malignant development and
progression. Here we show that in a mouse tumor model, tumor-derived VEGF acts as an
endocrine-like hormone to induce extramedullary hematopoiesis by targeting distal organs in the
host. In tumor-bearing mice, circulating VEGF induced hepatomegaly and splenomegaly owing to
vessel dilation, tortuosity and activation of hematopoiesis. Furthermore, VEGFR1 and VEGFR2
were primarily localized in blood vessels rather than hepatocytes or splenocytes, demonstrating
that alteration of angiogenic profiles modulates hematopoiesis in these organs. Stimulation of
extramedullary hematopoiesis sheds new light on complex biological functions of VEGF and
significantly increases our understanding of molecular mechanisms underlying VEGF-induced tumor
growth.
Introduction
Malignant tissues produce multiple growth factors and
cytokines to induce angiogenesis, which is essential for
tumor growth, invasion and metastasis [1,2]. Among
tumor-derived angiogenic factors, vascular endothelial
growth factor (VEGF) is probably one of the best-charac-
terized molecules. VEGF displays multiple physiological
and pathological functions by targeting both vascular and
non-vascular systems [3-5]. In developing embryos, dele-
tion of only one allele of the vegf gene results in severe
defects of early embryos that manifest impaired hemat-
opoiesis and collapse of the vascular system [6,7]. In the
adult, VEGF is required to maintain the integrity of the
vasculature and physiological functions, including
endothelial survival, vascular fenestration in several endo-
crine glands, neurotrophic effects, support of bone mar-
row hematopoiesis, wound healing, and reproductive
activity [8,9]. To maintain these multiple physiological
functions, optimal levels of VEGF expression are required
in various tissues and organs [10,11]. When optimal
expression levels are altered, VEGF often causes patholog-
ical disorders by triggering uncontrolled vascular
responses that include pathological vasculogenesis, ang-
iogenesis, and tissue edema. The plasticity features of
VEGF expression determine its involvement in a broad
spectrum of human diseases including malignant and
non-malignant disorders. For example, tissue hypoxia is
one of the key factors that elevate VEGF expressions in
both tumors and non-malignant disorders [12,13].
In tumors, VEGF is known to significantly contribute to
pathological angiogenesis, tortuosity of tumor vascula-
tures and vasculogenesis, which all together lead to accel-
erated growth rates of tumors, invasion and metastasis
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[14]. In addition to vascular effects, VEGF also mobilizes
mononucleic cells and probably endothelial progenitor
cells from bone marrow, whereas former enhances tumor
inflammation, the latter participates in vasculogenesis
[15,16]. VEGF-induced vascular tortuosity and leakiness
also provide a structural basis for tumor cell invasion into
the circulation system, leading to distal metastasis. In
addition to hematologous metastasis, recent work from
our laboratory and others demonstrates that VEGF is also
a potent lymphangiogenic factor, which promotes lym-
phatic metastasis [17-20].
Similar to the prototype member of VEGF, other members
in the VEGF family exhibit overlapping and sometimes
distinctive biological functions in both physiological and
pathological settings, depending on their abilities to acti-
vate a subset of VEGF receptors. While VEGFR2 is consist-
ently reported as a functional receptor to transduce
angiogenic, vasculogenic and vascular permeability activ-
ities, functional properties of VEGFR1 remain controver-
sial [21]. Probably, VEGFR-1 transduces both positive and
negative signals in endothelial and non-endothelial cells,
depending on the choice of experimental settings [21].
Additionally, high molecular forms of VEGF also bind to
neuropilin-1 and -2, which are involved in tumor growth
and metastasis [22,23].
Owing to the pivotal role of VEGF in regulation of patho-
logical angiogenesis and tumor growth, several anti-VEGF
drugs have been developed for cancer therapy. These
include neutralization of the VEGF ligand by antibodies
such as bevacizumab and small chemical compounds tar-
geting the receptor signaling pathways such as sorafenib
and sunitinib [24]. In general, clinical responses to these
drugs in combinations with chemotherpy are very encour-
aging and they become one of the key components of the
first-line therapeutic regimens for various human cancers
[25]. In the present study, we provide new evidence that
VEGF could induce extramedullary hemetapoiesis in adult
tumor-bearing mice. These findings suggest that VEGF




Female C57Bl/6 mice were anesthetized by Isoflurane
(Abbott Scandinavia) before all procedures. The experi-
ments were followed up to 4 weeks. Mice were sacrificed
by exposure to a lethal dose of CO2 followed by cervical
dislocation. All animal studies were reviewed and
approved by the animal care committee of the North
Stockholm Animal Board (Stockholm, Sweden). Antibod-
ies include a rat anti-mouse CD31 monoclonal antibody,
a rat anti-mouse erythroid cells (Ter119) monoclonal
antibody (BD Pharmingen, San Diego, CA, USA), a rat
anti-mouse VEGFR1 (MF1) antibody, a rat anti-mouse
VEGFR2 (DC101) antibody (ImClone Systems Inc., NY,
USA), and a rabbit anti-mouse polyclonal VEGFR-2 anti-
body (kindly provided by Dr. Rolf Brekken at University
of Texas Southwestern Medical Center).
Cell culture
Murine T241 fibrosarcoma is transfected with control vec-
tor and DNA constructs which stably express human
VEGF165 as previously described [5,26]. Tumor cell lines
were grown and maintained in Dulbecco's Modified
Eagles Medium (DMEM) (Sigma) with 10% heat-inacti-
vated fetal bovine serum.
Xenograft tumor model
Approximately 1 × 106 tumor cells were subcutaneously
injected into the dorsal region of each mouse. Tumor
growth was monitored on a daily basis. When tumors
reached approximately 1.0 cm3, the experiments were ter-
minated. Various tissues and organs were dissected and
fixed with 4% paraformaldehyde (PFA) overnight, fol-
lowed by transferring into PBS until further analysis. For
some analyses, a portion of each tissue was frozen at -
80°C until further use. In blockade experiments, VEGF
tumor-bearing mice were randomly divided into two
groups (n = 6-8/group) and received VEGFR1 or VEGFR2
blockades as previous described [4,5]. The treatment
started at day 2 after tumor implantation. Each mouse in
various groups received vehicle, anti-VEGFR1 (MF1,
Imclone Inc., 800 μg/mouse) or anti-VEGFR2 (DC101,
Imclone Inc., 800 μg/mouse) antibodies twice a week for
a total 2-week period.
Histological analysis and immunohistochemistry
Paraffin-embedded tissues including liver, spleen and
bone were sectioned in 5 μm thickness and stained with
hemtoxylin/eosin (H&E) according to a standard method
[5]. Liver sections were stained with an anti-Ter119 anti-
body as the primary antibody. After extensive washes with
PBS, sections were stained with a secondary antibody of
HRP-conjugated anti-rat IgG. Positive signals were devel-
oped by substrate DAB, followed by capturing under a
light microscope (40× magnification).
Cryostat tissue sections of 10 μm thickness were stained
according to a standard immunohistochemical procedure
[5]. Briefly, sections were incubated with primary anti-
bodies, including anti-CD31, Ter119, VEGFR1 or
VEGFR2, overnight at 4°C. After rigorous washes with PBS
for three times, sections were incubated for 1 hour at
room temperature with various secondary antibodies,
including a goat anti-rat Alexa-555-labeled antibody
(1:500), a FITC-labeled rabbit anti-rat IgG (1:300, Vector
Laboratories), a Cy5-labeled goat anti-rabbit antibody
(1:400, Chemicon International, Temecula, CA, USA),Journal of Angiogenesis Research 2009, 1:9 http://www.jangiogenesis.com/content/1/1/9
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which were used for either mono- or double-staining. Sec-
tions were mounted on glass-slides with Vectashield
mounting medium (Vector Laboratories). Positive signals
were photographed under a confocal microscopy (20×,
Zeiss Confocal LSM510 Microscope).
Results and Discussion
Our recent findings show that tumor-derived VEGF
induces a systemic syndrome in mice, manifesting a can-
cer-associated paraneoplastic syndrome [5]. Using the
same tumor model, ie., murine T241 fibrosarcoma model,
we studied the role of VEGF in modulation of hematopoi-
esis. In a xenograft model, implantation of T241-VEGF
tumors in mice led to hepatomegaly and splenomegaly
[5]. Histological examination of liver tissues showed that
visible hematopoietic islets in liver sections from T241-
VEGF tumor-bearing mice but not in liver sections of
T241-vector control tumor-bearing mice (Fig. 1). To fur-
ther validate the identity of hematopoietic islets, liver sec-
tions were stained with Ter119, a hematopoietic marker
for erythroblasts. Consistent with H&E staining, these
morphologically hematopoietic islets exhibited positive
signals of Ter119 (Fig. 1). Quantification analysis showed
a significant difference between T241-VEGF and T241-
vector groups (see ref [5]). Moreover, the sinusoidal
hepatic vasculature became highly dilated in livers of
T241-VEGF tumor-bearing mice but not in livers of T241-
vector tumor-bearing mice (Fig. 1). These findings dem-
onstrate that tumor-derived VEGF significantly contrib-
utes hepatic hematopoiesis and the vascular architecture
is significantly altered in this organ.
Because extramedullary hematopoiesis often occurs in the
spleen of mice, we next examined spleens of tumor-bear-
ing mice. Similar to livers, splenomegaly also existed in
T241-VEGF tumor-bearing mice [5]. Histological exami-
nation showed that apparent borders between the white
pulp (WP) and red pulp (RP) under physiological condi-
tions were vanished and were replaced by a mixture of WP
and RP without any distinctive borders throughout the
entire spleen of T241-VEGF tumor-bearing mice (Fig. 2).
Ter119 staining revealed that active hematopoiesis
occurred throughout the entire spleen tissue of T241-
VEGF tumor-bearing mice (Fig. 2). In markedly contrast,
Ter119 positive signals only present in the RP region in
the spleen of T241-vector tumor-bearing mice (Fig. 2).
These findings show that tumor-derived VEGF signifi-
cantly modulates extramedullary hematopoiesis in the
adult spleen by expansion of RP areas.
To delineate molecular mechanisms underlying systemic
VEGF-induced extramedullary hematopoiesis, VEGFR1
and VEGFR2 were detected in both liver and spleen tis-
sues. Interestingly, expression patterns of VEGFR1 and
VEGFR2 were restricted in blood vessels, but not in other
cell types including hepatocytes, splenocytes and stromal
cells (Fig. 3). Moreover, VEGF2 positive signals were gen-
erally enhanced while VEGFR1 signals were decreased in
both spleens and livers of T241-VEGF tumor-bearing mice
(Fig. 3). To further distinguish VEGFR1- and VEGFR2-
mediated signaling pathways in hematopoiesis, VEGFR1
and VEGFR2 specific blockades were used for treatments.
An anti-VEGFR2 specific monoclonal antibody com-
pletely restored histological structures of liver and spleen
in VEGF tumor-bearing mice, whereas VEGFR1 blockade
had no effect in these organs (Fig. 4). Consistent with his-
tological changes, VEGFR2 blockade completely normal-
ized hepatic sinusoidal vasculatures whereas VEGFR1
blockade lacked such an effect. These findings demon-
strate that VEGFR2 is a crucial receptor that mediates
extramedullary hematopiesis and tortuosity of vascula-
tures in these organs.
Although VEGF might directly promote extramedullary
hematopoiesis in liver and spleen, it was plausible that
VEGF-induced extramedullary hematopoiesis echoes
defective bone marrow (BM) hematopoiesis and thus rep-
resents a compensatory mechanism of BM deficiency. To
test this possibility, we histologically examined BM of
VEGF tumor-bearing mice. Markedly, VEGF tumor-bear-
ing mice suffered from a severe defect in BM by loosing
hematopoiestic cells relative to vector control BM (Fig. 5).
Interestingly, VEGFR2 blockade could largely restore
VEGF-induced BM defects while VEGFR1 blockade was
unable to rescue the defective phenotype (Fig. 5). Based
on these findings, it is likely that extramedullary hemat-
opoiesis resulted from defective BM hematopoiesis via
compensatory activation of this process in liver and
spleen.
The data presented in this study provide compelling evi-
dence that tumor-derived VEGF displays a profound effect
on the hematopoietic system. It appears that tumor-
derived VEGF enters into the circulation and acts on either
endothelial cells and/or hematopietic progenitor cells to
modulate hematopoiesis. Although molecular mecha-
nisms underlying VEGF-induced impairment of BM
hematopoiesis remain unknown, it is possible that VEGF
mobilizes BM hematopoietic stem cells to accumulate in
peripheral tissues and organs. Indeed, VEGF has been
reported to mobilize BM cells in tumor models and other
experimental settings [15,16]. Suppression of BM hemat-
opoiesis would in theory result in a decreased tumor
growth rate due to insufficient oxygen supply. In contrast,
in our experimental system we have found that VEGF
tumors grow at an accelerated rate relative to control
tumors [5,26]. There are several possible mechanisms to
explain these paradoxical findings: 1) VEGF also exhibits
potent angiogenic and vasculogenic activities, which sig-
nificantly facilitate blood perfusion in tumor tissues; 2)Journal of Angiogenesis Research 2009, 1:9 http://www.jangiogenesis.com/content/1/1/9
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Hepatic hematopoietic islets and vasculature Figure 1
Hepatic hematopoietic islets and vasculature. Liver sections from T241-VEGF and T241-vector tumor-bearing mice 
were stained with H&E (A and B), an anti-Ter119 antibody (C and D), or anti-CD31 antibody (E and F). Arrows in panels A, C, 
and D point to hematopoietic islets. Arrows in E and F point to hepatic sinusoidal microvessels. CV = central vein. HC = hepa-
tocyte. Bar in panels A-D = 100 μm. Bar in panels E and F = 50 μm.Journal of Angiogenesis Research 2009, 1:9 http://www.jangiogenesis.com/content/1/1/9
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Hypoxia is known to increase tumor invasion and spread.
Indeed, necrotic cores are often observed in VEGF tumors
relative to control tumors. These findings suggest that
VEGF tumors suffer from higher degrees of tissue hypoxia
than control tumors, and hypoxia would persuade tumor
cells to expand to healthy neighboring tissues; 3) VEGF-
mobilized BM-derived inflammatory cells significantly
contribute to tumor growth by producing a range of ang-
iogenic factors and cytokines, and 4) Extramedullary
hematopoiesis compensates oxygen supply and supports
tumor growth. However, this compensatory mechanism
may not sufficiently rescue the defective phenotype of BM
hematopoiesis.
Spleno-extramedullary hematopoiesis Figure 2
Spleno-extramedullary hematopoiesis. Spleen sections from T241-VEGF and T241-vector tumor-bearing mice were 
stained with H&E (A and B), or were double stained an anti-Ter119 antibody and propidium iodide (PI) (C and D). Dashed lines 
in panel B encircle white pulp (WP). RP = red pulp. Hematopietic cells from the erythrocyte lineage were labeled with Ter119 
(green) and all cell nuclei were labeled with PI (red). Bar in panel A and B = 100 μm. Bar in C and D = 50 μm.Journal of Angiogenesis Research 2009, 1:9 http://www.jangiogenesis.com/content/1/1/9
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Our findings also show that VEGF targeted therapy has a
profound impact on multiple tissues and organs [5]. In
the hematopoietic system, anti-VEGF drugs might signifi-
cantly improve BM hematopoiesis and anemia in
patients. However, the distinct functions mediated by
VEGFR1 and VEGFR2 should be separated. While VEGFR1
is distributed in hematopoietic cells such as monocytes
and neutrophils, VEGFR2 is the key receptor to mediate
hematopoietic signals [5]. Consistent with our findings,
genetic deletion of vegfr2 gene in mice results in severe
defects of both vascular and hematopoietic systems in
mouse embryos [6,7]. In contrast, deletion of VEGFR1
does not seem to significantly affect hematopoiesis [6,7].
Most currently available drugs such as bevacizumab,
sunitinib and sorafenib do not allow us to distinguish the
biological functions mediated by VEGFR1 and VEGFR2
[21]. It is unclear if VEGFR2 specific blockade would pro-
duce better clinical outcomes than currently available
VEGF inhibitors in the clinic. However, it is known that
VEGFR1 could also mediate negative signals of angiogen-
Localization of VEGFR1 and VEGFR2 in liver and spleen tissue sections Figure 3
Localization of VEGFR1 and VEGFR2 in liver and spleen tissue sections. Liver (A and B) and spleen (C and D) tissue 
sections from T241-VEGF and T241-vector tumor-bearing mice were double stained with monoclonal antibodies specific for 
mouse VEGFR1 (red) or VEGFR2 (blue). Yellow arrows point to double positive signals and white arrowheads indicate single 
positive singles. Bar = 50 μm.Journal of Angiogenesis Research 2009, 1:9 http://www.jangiogenesis.com/content/1/1/9
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esis under both physiological and pathological conditions
[21].
Neutralization of VEGF-induced systemic disorders in
cancer patients is probably an important mechanism for
cancer therapy although antiangiogenesis is one of the key
mechanisms of anti-VEGF drugs. Consistent with this
notion, suppression of tumor size has not been positively
correlated with clinical benefits of these antiangiogenic
drugs [27]. Our current findings provide new evidence
that VEGF targets multiple tissues and organs and that
anti-VEGF therapy may have a global impact in cancer
patients.
Conclusions
Our findings show that tumor-derived VEGF modulates
the hematopoietic system by suppression of BM-hemat-
opoiesis, leading to activation of extramedullary hemat-
opoiesis in liver and spleen. Modulation of hematopoiesis
is mediated by VEGFR2 but not by VEGFR1. These results
demonstrate that tumor-derived VEGF has a profound
impact on multiple tissues and organs and these broad
systemic effects might further facilitate tumor growth and
Histology and vasculature of liver and spleen treated with VEGFR blockades Figure 4
Histology and vasculature of liver and spleen treated with VEGFR blockades. Spleen (A-C) and liver (D-F) tissue 
sections from buffer- (A, D, and G), anti-VEGFR1- (B, E and H), or anti-VEGFR2-(C, F and I) treated T241-VEGF-bearing mice 
were stained with H&E (A-F) or anti-CD31 (G-I). Arrows in panels of G-I indicate microsinusoidal vasculatures in liver sec-
tions. CV = central vein. Bar = 50 μm.Journal of Angiogenesis Research 2009, 1:9 http://www.jangiogenesis.com/content/1/1/9
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metastasis. Additionally, circulating VEGF derived from
the malignant tissue also contributes to development of
cancer-associated systemic disorders, which significantly
jeopardize quality of life and survival of cancer patients.
Thus, anti-VEGF therapy may produce more profound
beneficial effects in cancer patients by improving hemat-
opoiesis and other systemic functions of cancer patients.
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